Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Anthony M. Marchese"'
Autor:
Anthony M. Marchese, Raj Kalkeri, Muruga Vadivale, Nungruthai Suntronwong, Seth Toback, Yong Poovorawan
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 620-628 (2023)
Introduction Approximately half of the 13.4 billion COVID-19 vaccine doses administered globally were inactivated or viral vector platforms. The harmonization and optimization of vaccine regimens has become a key focus of policymakers and health-care
Externí odkaz:
https://doaj.org/article/4bcfdc41c6734d9cb89f5712dd51638a
Autor:
Nita Patel, Jessica F. Trost, Mimi Guebre-Xabier, Haixia Zhou, Jim Norton, Desheng Jiang, Zhaohui Cai, Mingzhu Zhu, Anthony M. Marchese, Ann M. Greene, Raburn M. Mallory, Raj Kalkeri, Filip Dubovsky, Gale Smith
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Monovalent SARS-CoV-2 Prototype (Wuhan-Hu-1) and bivalent (Prototype + BA.4/5) COVID-19 vaccines have demonstrated a waning of vaccine-mediated immunity highlighted by lower neutralizing antibody responses against SARS-CoV-2 Omicron XBB sub-
Externí odkaz:
https://doaj.org/article/ad7456950c5a471aa62cd2ee79cad670
Autor:
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, Seth Toback
Publikováno v:
Vaccines, Vol 12, Iss 7, p 802 (2024)
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-
Externí odkaz:
https://doaj.org/article/4a6215e46a214139a474118ea9ab0af3
Autor:
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Angela Miller, Seth Toback
Publikováno v:
Vaccines, Vol 12, Iss 1, p 83 (2024)
As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool to reduce the COVID-19 burden. Vaccine reactogenicity and the impact on work productivity/daily activities are recognized as contributing factors to vaccine hesitancy. To
Externí odkaz:
https://doaj.org/article/a733523b797943a093085e517ba4b0e2
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract The precise mechanism by which many virus-based vectors activate immune responses remains unknown. Dendritic cells (DCs) play key roles in priming T cell responses and controlling virus replication, but their functions in generating protecti
Externí odkaz:
https://doaj.org/article/9f635bc15de044ad91eccd5d62ec3467
Autor:
Zachary T. Olmsted, Amir Hadanny, Anthony M. Marchese, Marisa DiMarzio, Olga Khazen, Charles Argoff, Vishad Sukul, Julie G. Pilitsis
Publikováno v:
Frontiers in Pain Research, Vol 2 (2021)
Over 50% of the 34 million people who suffer from diabetes mellitus (DM) are affected by diabetic neuropathy. Painful diabetic neuropathy (PDN) impacts 40–50% of that group (8.5 million patients) and is associated with a significant source of disab
Externí odkaz:
https://doaj.org/article/3850f025429c4d55974cfeedfd9983c3
Autor:
Anthony M. Marchese, Xiang Zhou, John Kinol, Eddie Underwood, Wayne Woo, Alice McGarry, Hadi Beyhaghi, Germán Áñez, Seth Toback, Lisa M. Dunkle
Publikováno v:
Vaccine. 41:3461-3466
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41567ae3753b43163c5889bdc987069d
https://doi.org/10.1016/j.vaccine.2023.04.054
https://doi.org/10.1016/j.vaccine.2023.04.054
Autor:
Seth Toback, Anthony M. Marchese, Brandy Warren, Sondos Ayman, Senka Zarkovic, Islam ElTantawy, Raburn M. Mallory, Matthew Rousculp, Fahed Almarzooqi, Bartlomiej Piechowski-Jozwiak, Maria-Fernanda Bonilla, Agyad Ebrahim Bakkour, Salah Eldin Hussein, Nawal Al Kaabi
This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity of NVX-CoV2373 as a heterologous booster compared to BBIBP-CorV when utilized as a homologous booster. Approx
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f95db6f040696e49e02517b5772c130
https://doi.org/10.1101/2023.03.24.23287658
https://doi.org/10.1101/2023.03.24.23287658
Autor:
Anthony M. Marchese, Xiang Zhou, John Kinol, Eddie Underwood, Wayne Woo, Alice McGarry, Hadi Beyhaghi, Germán Áñez, Seth Toback, Lisa M. Dunkle
PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant spike protein COVID-19 vaccine (NVX-CoV2373) demonstrated that the vaccine was safe and efficacious (vaccine efficacy, VE= 90%) for the prevention of symptomatic COVID-19. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9607f38730e2a019e34491db4c983199
https://doi.org/10.1101/2023.03.17.23287306
https://doi.org/10.1101/2023.03.17.23287306
Publikováno v:
Curr Opin Virol
Hepatitis B virus (HBV) causes chronic infections that are associated with immune dysfunction. Though T cell impairment is perhaps the most prominent immune change contributing to viral persistence, HBV interaction with the innate immune system is al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af85238168466a85321c0c87bed9acec
https://doi.org/10.1016/j.coviro.2021.04.003
https://doi.org/10.1016/j.coviro.2021.04.003